This was a result from higher revenue, partially offset by increased distribution costs which rose in tandem with the higher sales achieved and increased R&D spending in the quarter.
Shares in Hyphens Pharma have surged some 10.9% higher to 30 cents as at 10.50am following the announcement of its 3QFY2022 ended September results earlier on Nov 10.
In its 3QFY2022 business update, specialty pharmaceutical and consumer healthcare group Hyphens Pharma reported an almost three-fold y-o-y jump in its profit after tax to $4.0 million from $1.1 million a year ago.
